Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Vanguard Value Index Fund ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B), while Vanguard Value Index Fund ETF trades at $225.17. Which is the better fit depends on your goals.
| VRTX | VTV | |
|---|---|---|
Market Cap | $132.79B | — |
Sector | Health | — |
52-Week High | $529.65 | $225.35 |
52-Week Low | $376.62 | $179.43 |
Enterprise Value | $126.92B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
VTV trades at $224.31, up 0.42% today, with a bullish technical outlook supported by moving averages and near-term resistance at $225. The ETF has gained 22% year-to-date in 2026, outperforming growth-focused peers as value strategies attract attention amid flat market growth. A dividend of $1.08 is scheduled for June 2026.
The outlook remains positive given value's recent momentum and low exposure to tech volatility, but risks include Federal Reserve policy shifts and stretched RSI levels. Institutional activity is mixed, with some trimming positions while others increase stakes, reflecting cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
